Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics, today announced that the European Patent Office (EPO) has issued a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback